Tech Company Financing Transactions

Casma Therapeutics Funding Round

Casma Therapeutics, based in Cambridge, secured $50 million in investment from The Column Group, Eventide Asset Management and Schroder Adveq.

Transaction Overview

Company Name
Announced On
9/11/2020
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors

The Column Group (Lead Investor) (Millie Ray)

Eventide Asset Management (Finny Kuruvilla)

Schroder Adveq

Third Rock Ventures (Cary Pfeffer)

Proceeds Purpose
The proceeds from the financing will allow the company to advance their TRPML1 agonist program into development for muscular dystrophy, as well as continue to develop the Autophagy Degrader Platform (ADP).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 201
Cambridge, MA 02139
USA
Phone
Undisclosed
Email Address
Overview
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy -- pioneering novel therapeutic strategies to address unmet medical needs.
Profile
Casma Therapeutics LinkedIn Company Profile
Social Media
Casma Therapeutics Company Twitter Account
Company News
Casma Therapeutics News
Facebook
Casma Therapeutics on Facebook
YouTube
Casma Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Keith Dionne
  Keith Dionne LinkedIn Profile  Keith Dionne Twitter Account  Keith Dionne News  Keith Dionne on Facebook
Chief Operating Officer
Frank Gentile
  Frank Gentile LinkedIn Profile  Frank Gentile Twitter Account  Frank Gentile News  Frank Gentile on Facebook
Chief Scientific Officer
Leon Murphy
  Leon Murphy LinkedIn Profile  Leon Murphy Twitter Account  Leon Murphy News  Leon Murphy on Facebook
Vice President
Daniel Ory
  Daniel Ory LinkedIn Profile  Daniel Ory Twitter Account  Daniel Ory News  Daniel Ory on Facebook
Vice President
Jeffrey Saunders
  Jeffrey Saunders LinkedIn Profile  Jeffrey Saunders Twitter Account  Jeffrey Saunders News  Jeffrey Saunders on Facebook
VP - Finance
Colleen DeSimone
  Colleen DeSimone LinkedIn Profile  Colleen DeSimone Twitter Account  Colleen DeSimone News  Colleen DeSimone on Facebook
VP - Human Resources
Caren Block
  Caren Block LinkedIn Profile  Caren Block Twitter Account  Caren Block News  Caren Block on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/11/2020: BinSentry venture capital transaction
Next: 9/11/2020: Korro Bio venture capital transaction

 

Share this article

 


News on VC Transactions

We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary